Fibronectin type III domain containing 4 alleviates myocardial ischemia/reperfusion injury via the Nrf2-dependent

Xiaoming Xu1, Lu Peng1, Yunlong Xia1

  • 1Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.

PubMed

Insights

Fibronectin type III domain containing 4 (FNDC4) protects the heart from injury after ischemia and reperfusion by reducing oxidative stress and cell death. This finding suggests FNDC4 as a potential therapeutic target for heart damage.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Fibronectin type III domain containing 4 (FNDC4) is homologous to FNDC5, known for cardiometabolic benefits.
  • FNDC4 is implicated in fat metabolism and inflammation.
  • Its role in myocardial ischemia/reperfusion (MI/R) injury requires detailed characterization.

Purpose of the Study:

  • To investigate the role of FNDC4 in MI/R injury.
  • To elucidate the underlying mechanisms of FNDC4's action in the heart.
  • To assess FNDC4 as a potential therapeutic target for MI/R damage.

Main Methods:

  • Established MI/R mouse models and analyzed plasma and myocardial FNDC4 levels.
  • Utilized FNDC4 knockout and overexpression mouse models.
  • Conducted in vitro studies using hypoxia-reoxygenation (H/R) on cardiomyocytes.
  • Performed RNA-sequencing and pathway analysis.

Main Results:

  • Plasma and myocardial FNDC4 levels were significantly reduced in MI/R injury.
  • FNDC4 deficiency exacerbated MI/R-induced cardiac dysfunction, infarct size, and apoptosis.
  • FNDC4 overexpression ameliorated cardiac function and reduced injury markers.
  • In vitro, FNDC4 protected cardiomyocytes against H/R-induced apoptosis.
  • The ERK1/2-Nrf2 pathway mediated FNDC4's antioxidative and protective effects.

Conclusions:

  • FNDC4 plays a crucial protective role against MI/R injury.
  • Cardioprotection is achieved by mitigating oxidative stress and cardiomyocyte apoptosis via the ERK1/2-Nrf2 pathway.
  • FNDC4 represents a promising therapeutic target for managing MI/R damage.